Drug Discovery at Neurogeneration

Neurogeneration has established a highly-focused drug discovery platform built on the company’s deep knowledge of inhibitors and inflammatory events as causative factors of synaptic damages triggered by ABeta oligomers ¬†accumulation. The company’s lead compound, NGN-9 is currently undergoing pharmacokinetic and hit identification studies. Neurogeneration selective novel small molecules therapy may become ¬†a new treatment for… Read More